All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Mucosa-associated lymphoid tissue (MALT) lymphoma is a type of marginal zone lymphoma belonging to the indolent non-Hodgkin lymphoma (NHL) entity.1 Histopathological markers of MALT lymphoma include the presence of lymphoepithelial lesions, follicular colonization and plasmacellular differentiation.2 Although MALT lymphoma can affect any organ, gastric presentation is responsible for up to 50% of all cases.2
The impact of initial depth of remission to first-line therapy on progression-free survival (PFS) in patients with gastric MALT lymphoma has not yet been established. Barbara Kiesewetter-Wiederkehr, Medical University of Vienna, AT, and colleagues investigated patient responses to first-line therapy and subsequent relapse patterns. The study which was published in Cancers in February placed a major focus on a sub cohort of patients that had received Helicobacter pylori (H. pylori) eradication therapy.2 The Lymphoma Hub hereby presents a summary of the results.
Chronic H. pylori gastritis has been associated with gastric MALT lymphomagenesis, and therefore H. pylori eradication is the standard of care (SoC) for patients with the condition.3 Antibiotic treatment demonstrates favorable outcomes in patients with gastric MALT lymphoma, inducing 5-year survival rates as high as 90%. However, follow-up biopsies uncover persistent disease in around one third of patients previously classed as being in complete remission (CR).2 It has been suggested that persisting or residual disease may be affected by the level of remission following first-line treatment. Uncovering a relationship between depth of remission and patient outcome may influence the clinical management of patients with gastric MALT lymphoma.2
Table 1. Baseline characteristics of gastric MALT lymphoma patient cohort
MALT-IPI, MALT lymphoma prognostic index; IQR, interquartile range *IE, confined to the stomach †IIE, presenting with local lymph node involvement ±IIIE, presenting with distant lymph node involvement §IV, disseminated disease |
|
Characteristic |
% of patients (n = 137) |
Sex, Female |
51 |
Median age, years (range) |
63 (22 – 85 years) |
Age ≥ 70 years |
28 |
Stage of disease-Ann Arbor Ann Arbor IE* Ann Arbor IIE† Ann Arbor IIIE± Ann Arbor IV§ |
66 23 1 10 |
MALT-IPI (available in 122 patients) Low risk Intermediate risk High risk |
62 33 6 |
Further clinical features Helicobacter pylori positive Plasmacellular differentiation Autoimmune disorder Paraproteinemia |
68 22 20 27 |
Median follow-up time, months (IQR) |
56.2 (26.3–111.6) |
Table 2. Front-line treatment approaches
H. pylori, Helicobacter pylori |
|
Treatment |
% of patients |
First-line treatment overall collective (N = 137) H. pylori eradication Systemic treatment (chemo-/immunotherapy) Local therapy (radiation, surgery) Watch and wait |
70 23 4 3 |
Table 3. Patient outcomes to first-line treatments
CR, complete remission; H. pylori, Helicobacter pylori; ORR, overall response rate; PD, progressive disease; PR, partial remission; SD, stable disease |
|||||
Response to treatment, % |
ORR |
CR |
PR |
SD |
PD |
Overall collective (n = 128)
|
67 |
48 |
19 |
30 |
3 |
H. pylori eradication therapy (n = 93)
|
58
|
38
|
20
|
39
|
3 |
Systemic treatment (n = 30) |
90
|
77
|
13
|
7
|
3 |
Local treatment (n = 5) |
100
|
80
|
20 |
- |
-
|
Table 4. Patient survival outcomes at a median follow-up of 56.2 months
CI, confidence interval; CR, complete response; H. pylori, helicobacter pylori; PFS, progression-free survival; PR, partial remission; SD, stable disease; TTNT, time to next treatment *This difference remained significant after multivariate correction for MALT-IPI factors |
||
Outcome |
Overall collective (N = 137) |
H. pylori eradication cohort (n = 96) |
Relapse/progression, % |
52 |
49 |
Median estimated PFS, months (95% CI) |
34.2 (16.0–52.4) |
27.6 (22.6–32.6) |
PFS, months Objective response Non-responders p |
68.3 17.3 < 0.001 |
49.0 17.3 < 0.001 |
Median estimated PFS CR vs PR, months CR PR p |
94.8 28.5 0.007 |
109.4 27.6 0.020* |
TTNT Objective response SD p |
47.5 15.3 0.001 |
30.3 15.4 0.008 |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?